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Abstract: Sample preparation is a significant challenge for detection and sensing technologies, 
since the presence of blood cells can interfere with the accuracy and reliability of virus detec-
tion at the nanoscale for point-of-care testing. To the best of our knowledge, there is not an 
existing on-chip virus isolation technology that does not use complex fluidic pumps. Here, we 
presented a lab-on-a-chip filter device to isolate plasma and viruses from unprocessed whole 
blood based on size exclusion without using a micropump. We demonstrated that viruses 
(eg, HIV) can be separated on a filter-based chip (2-µm pore size) from HIV-spiked whole 
blood at high recovery efficiencies of 89.9% ± 5.0%, 80.5% ± 4.3%, and 78.2% ± 3.8%, for 
viral loads of 1000, 10,000 and 100,000 copies/mL, respectively. Meanwhile, 81.7% ± 6.7% of 
red blood cells and 89.5% ± 2.4% of white blood cells were retained on 2 µm pore–sized filter 
microchips. We also tested these filter microchips with seven HIV-infected patient samples and 
observed recovery efficiencies ranging from 73.1% ± 8.3% to 82.5% ± 4.1%. These results 
are first steps towards developing disposable point-of-care diagnostics and monitoring devices 
for resource-constrained settings, as well as hospital and primary care settings.
Keywords: microchip, filtration, virus isolation, plasma separation, point-of-care
Introduction
Pandemic diseases including HIV , malaria, and TB, as well as emerging infectious 
diseases such as influenza H1N1 have raised serious challenges for global health and 
homeland security. For instance, HIV has caused more than 25 million deaths since the 
first reported case of AIDS in 1981, and currently there are approximately 33.3 million 
people living with HIV .1 Emerging endemics present grand threats to the public 
health. For example, H1N1 rapidly spread worldwide and caused a global pandemic 
in 2009,2,3 and a similar strain led to over 50 million deaths in 1918.3 To prevent and 
control these highly contagious infectious diseases, there is a need for implementing 
rapid and simple diagnostic technologies to detect early cases in the field. As such, 
microfluidic systems, due to their portability, affordability, and high sensitivity, have 
become promising technologies to develop point-of-care (POC) diagnostics.4–7
Currently, POC diagnostics require on-chip sample processing, including plasma 
separation from whole blood as an initial step.8,9 For example, inclusion of blood cells 
or components such as hemoglobin and lactoferrin may inhibit DNA polymerase 
in polymerase chain reaction (PCR) analysis and lead to inaccurate quantification 
or even amplification failure.10 Similarly, inhibitors from whole blood can interfere 
with enzyme-linked immunosorbent assay (ELISA) and result in low sensitivity and 
specificity.11,12 In addition, reducing the concentration of cellular components of blood, 
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and separating viruses in plasma using a rapid system may 
increase the capture efficiency microfluidic-based viral detec-
tion platforms.13,14 This is particularly important for optical 
sensors, since the presence of blood cells in the sample can 
negatively affect the optical detection path and compromise 
accuracy. Detection technologies such as whispering gallery–
mode devices,15 plasmon resonance devices,16 and photonic 
crystals,17 can benefit from the preremoval of nontargeted 
cells from whole blood to enhance the capture efficiency 
of targeted pathogens and proteins. In a clinical laboratory 
setting, plasma separation can simply be performed by 
centrifugation, whereas it remains a challenge at the POC, 
especially in resource-constrained settings due to lack of 
laboratory infrastructure.18–20 Hence, simple, inexpensive, 
and rapid plasma separation on-chip is urgently needed to 
facilitate POC diagnosis.
There have been microfluidic approaches to achieve on-
chip plasma separation via driving forces such as centrifugal 
force,21,22 capillary force,23 and the Zweifach–Fung effect.24 
However, these approaches have inherent shortcomings 
that render them not suitable for POC testing. For example, 
centrifugation-based compact-disk chips require electricity 
for high-speed rotation.21,22 Although capillary forces can be 
utilized to extract plasma to remove the need for electricity, 
small volumes of plasma can be extracted (a few nanoliters 
to microliters),25 which may be insufficient for conventional 
detection methods such as PCR or ELISA. To improve the 
yield, a continuous cross-flow device was designed to separate 
blood cells in microchannels at high flow rates.24 Despite 
enhanced plasma yields, this device requires accurate flow 
rates and a long fractionation time, which may not be ideal to 
achieve rapid detection of infectious agents at resource-con-
strained settings. Recently, plasma separation on-chip can also 
be achieved using a H2O2-powered pump26 or degas-driven 
flow in evacuated polydimethylsiloxane devices.25 However, 
the demanding storage conditions for H2O2 or vacuum limits 
the shelf life of these devices. Thus there is an unmet need to 
develop simple, robust sample-processing devices that can 
achieve rapid plasma separation to facilitate POC testing.27
Microfilters with pore sizes ranging from 5 to 30 µm 
have been used to isolate plasma from whole blood;28 
however, these approaches focus on cells. In contrast, we 
demonstrated isolation of viruses using small pore sizes 
(1–2 µm), which has not yet been reported. We separated 
viruses, which were 110–146 nm in size,29 from whole 
blood using a microchip with 1–2 µm diameter porous 
filter membranes, which can be used as a preliminary 
on-chip step to detect viruses from whole blood by 
immunocapture.13,14 We used HIV as a relevant virus model, 
and validated this microchip using hematological analysis 
and reverse transcription quantitative PCR (RT-qPCR). The 
presented work is the first demonstration of a simple, rapid, 
pump-free, antibody-free pathogen isolation device, which 
can reliably recover infectious agents using size-based 
separation from unprocessed whole blood. The presented 
microchip has broad potential applications; for instance, it 
can be coupled with existing battery-operated diagnostic 
tools, or integrated with microchip ELISA or PCR as a 
sample preparation module for POC testing.
Materials and methods
Device fabrication
The device consisted of four layers of poly(methyl methacry-
late) (PMMA) (McMaster-Carr, Atlanta, GA) and four layers 
of double-sided adhesive (DSA) (iTapestore, Scotch Plains, 
NJ), and a filter membrane (Figure 1A). The device was fab-
ricated utilizing a laser cutter, as previously described.4,7,14,30,31 
The device had outer dimensions of 25 × 40 mm. PMMA and 
DSA layer thicknesses were 1.5 mm and 50 µm, respectively. 
There was a circular opening with a diameter of 800 µm on 
the first PMMA layer to allow for blood injection into the 
inlet chamber. On this layer of PMMA, there was a rect-
angular opening (7.7 × 8.1 mm2) to collect plasma at the 
outlet chamber. The second PMMA layer had two separate 
rectangular openings (7.7 × 8.1 mm2). Underneath the sec-
ond PMMA layer was a Whatman nuclepore polycarbonate 
track-etched membrane with low protein-binding capacity 
(Fisher Scientific, Pittsburgh, PA), and pore sizes ranging 
from 0.4 to 3 µm in diameter. The third PMMA layer con-
tained two rectangular openings, which were connected by 
a channel (1.7 × 7.8 × 1.5 mm3). The fourth PMMA layer 
had no openings. These four PMMA layers and one layer 
of filter membrane were assembled via four layers of DSA 
(50 µm in thickness). Once assembled, the filter device had 
two rectangular chambers (100 µL) above and below the filter 
membrane (Figure 1B). The rectangular chamber under the 
filter membrane was connected to the outlet chamber by a 
microfluidic channel.
Device operation
To investigate the microchip performance, we evalu-
ated the device operation in a range of flow rates 
using a micropump. After we validated the chip operation 
using a flow-controlled system, we utilized manual flow 
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for virus separation by pipetting, eliminating the need for 
a micropump. The filtration process included injection of 
blood and continuous wash with phosphate-buffered saline 
(PBS, pH 7.4). First, 40 µL of de-identified whole blood 
purchased from Blood Research Component (Cambridge, 
MA) was injected into the inlet chamber using a micropump 
(Programmable Syringe Pump, Sarasota, FL). Next, a mini-
mum of 200 µL of PBS was injected using a micropump 
at flow rates of 100, 200, 300, 400, and 500 µL/min. These 
flow rates covered a broad flow-rate range before evaluating 
manual pipetting. The injection of PBS allowed the solution 
in the inlet chamber to replenish as separated plasma was 
pushed out from the outlet chamber (Figure 1D). Red blood 
cells (RBCs) and white blood cells (WBCs) were retained 
by the filter membrane, since their sizes exceed the pore 
size of the filter membrane. The injected PBS volume used 
in this study varied from 200 to 500 µL so that the inlet 
chamber could be completely washed. Following the wash, 
plasma was collected from the outlet chamber using a 
syringe with a tubing with an inner diameter of  0.05 cm 
(VWR Scientific, West Chester, PA) attached. The tubing 
was pushed from the outlet through the channel to the 
chamber under the membrane. This approach maximized 
the collection volume, and the volume of collected plasma 
was measured using a pipette.
For virus isolation from whole blood, we did not use a 
syringe pump. We manually introduced HIV-spiked whole 
blood samples into the microchip using a pipette. HIV sub-
type C intact particles were isolated from a clinical sample 
and co-cultured in peripheral blood mononuclear cells using 
a standard protocol. HIV particles were recovered using the 
(1 and 2 µm filter membranes) microchip and compared 
to centrifugation at 1000 g for 10 minutes (chart as shown 
in Figure 1C). Forty µL of blood sample was spiked with 
cultured HIV viruses (with final concentrations of 105, 104, 
and 103 copies/mL). The spiked samples were loaded into the 
microchip using a pipette and manually washed with 300 µL 
of PBS using a manual pipette. The filtration process took 
approximately 1 minute to complete.
Hematological analysis
D3 Hematology Analyzer (Drew Scientific, Dallas, TX) was 
used for hematological analysis. The machine was calibrated 
and maintained according to the manufacturer’s instruc-
tions. For hematological analysis, 10 µL of blood sample or 
plasma filtrate was analyzed to measure the concentration 
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Figure 1 (A–E) Design of the size-based filter microchip. (A) Assembly of a size-based filter microchip; (B) functionality of the size-exclusion-based filter microchip (i) cross-
section of the assembled device, (ii) injection of blood into the inlet through a pipette, (iii) injection of PBS into the inlet chamber to wash platelets and plasma through the 
microchannel and into the output channel, (iv) collection of plasma from the outlet; (C) the experimental chart for validation of virus recovery using filter microchips; (D) 
the device during filtration; (E) close-up of the plasma separated by the filter membrane.
Abbreviations: PBS, phosphate-buffered saline; RT-PCR, reverse transcriptase–polymerase chain reaction.
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of blood components, ie, RBCs, WBCs, and platelets. The 
passage rate was calculated as follows:
Pass  rate (%) 
Conc trationV olume of filtrate filtrate
age
en
=
×
C ConcentrationV olume of input blood blood ×
× 100
 (1)
where concentrationfiltrate is the concentration of WBCs, 
RBCs, and platelets in the filtrate, and concentrationblood is 
the concentration of WBCs, RBCs, and platelets in blood 
before filtration.
Quantification of HIV by RT-qPCR
Plasma filtrate containing HIV subtype C was quantified 
using RT-qPCR.32 HIV-1 RNA was first extracted using the 
QIAamp Viral RNA Mini Kit (Qiagen, Valencia, CA) accord-
ing to the manufacturer’s instructions. In the RT reaction 
(20 µL), the master mixture contained 10 µL of 2 × core 
RT buffer, 2 µL of 10 µM of reverse primer LTR-R2 (5′-
GTCTGAGGGATCTCTCTAGTTACCAG-3′), 0.5 µL of 
AffinityScript (Applied Biosystems, Carlsbad, CA), and 
7.5 µL of HIV-1 RNA. The RT reaction was carried out at 
25°C for 5 minutes, 45°C for 60 minutes, and 95°C for 3 
minutes, on the GeneAmp PCR System 9700 (Applied Bio-
systems). In the following qPCR (50 µL), the master mixture 
consisted of 1 × core PCR buffer, 0.4 µM of forward primer 
LTR-F (5′-TAAAGCTTGCCTTGAGTGCT-3′) and reverse 
primer LTR-R2, 0.2 µM of TaqMan probe LTR-P (JOE as 
the fluorophore and TAMRA as the quencher), 2.5 U of 
SureStart Taq polymerase, and 10 µL of cDNA template. The 
amplification reaction was carried out at 25°C for 5 minutes 
and then at 95°C for 10 minutes, and it was followed by 50 
two-step cycles of 60°C for 1 minute and 95°C for 30 seconds 
on the 7300 Real-Time PCR System (Applied Biosystems). 
In addition, seven discarded and de-identified HIV-infected 
whole blood samples were collected from Massachusetts 
General Hospital with the approval of the Institutional Review 
Board (protocol: 2009P000749). These patient samples were 
processed on-chip as the spiked samples described above. The 
recovery of HIV was determined by the following formula, in 
which the parameter of volume was omitted since the sample 
volume of ultracentrifugation and microchip separation was 
adjusted in RNA extraction.
Recovery (%)
HIV viral load in the filtrate sample
HIV vira
=
l l load in the centrifugation sample (control)
×100%
  (2)
The sample volume processed in centrifugation was 
adjusted to 40 µL, which was equivalent to the sample volume 
processed on-chip.
Results and discussion
In this study, we developed an on-chip filtration method based 
on size exclusion, characterized the filter device for plasma 
filtration from various aspects including pore size, flow rate, 
and wash volume, and finally applied it to HIV isolation 
from unprocessed whole blood. Blood components have 
different sizes; the average diameters of RBCs, WBCs, and 
platelets are 6–8 µm, 6–20 µm (depending on the cell types, 
including basophils, eosinophils, lymphocytes, monocytes, 
and neutrophils), and 1.5–3.5 µm,33 respectively. Thus, we 
used four different filters with varying pore sizes (0.4, 1, 2 
and 3 µm) to explore the capability of a filter membrane 
assembled in a microfluidic device to separate plasma, which 
is often used as a standard sample type for clinical diagnosis 
(eg, HIV viral load measurement). Also, we evaluated the 
effects of flow rate and wash volume on passage rates of blood 
components so as to minimize their presence in the filtrate. 
Lastly, we investigated the on-chip recovery of HIV particles, 
which have diameters ranging from 110 to 146 nm,29 from 
whole blood spiked with HIV or from HIV-infected patient 
blood samples.
We evaluated the effect of pore size on plasma separa-
tion using four filter membranes of different pore sizes 
(0.4, 1, 2, and 3 µm) and measured the passage rates of blood 
components. For the pore sizes ranging from 0.4 to 3 µm, 
WBC concentrations in the filtrate were below 0.3 × 103/
µL, compared to 6.5 × 103/µL in whole blood (Figure 2A); 
the RBC concentrations in the filtrate were less than 0.45 × 
106/µL, compared to 5.0 × 106/µL in whole blood (Figure 2B); 
and the platelet concentrations in the filtrate were below 
28.5 × 103/µL, compared to 203.7 × 103/µL in whole blood 
(Figure 2C). The size constraint by the filter was also reflected 
in the passage rates of these blood components in the filtrate 
(Figure 2D). For the pore size of 0.4 µm, the passage rates 
of WBCs, RBCs, and platelets were below 2.1%, indicating 
that these blood components can be separated from plasma 
by size exclusion–based filter microchips (Figure 2D). It was 
also observed that by using a 3 µm pore size microchip, a 
considerable amount of WBCs and RBCs passed through 
the filters, with the passage rate increasing to 25.1% and 
49.7%, respectively. The passage rates of platelets were 
47.7%, 67.7%, and 74.6%, using microchips with pore sizes 
of 1, 2, and 3 µm, respectively. These results indicated that 
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Figure 2 (A–D) Comparison of 0.4, 1, 2 and 3 µm pore–sized membranes for blood component filtration. In this experiment, 40 µL of blood was injected into the inlet 
chamber, and it was subsequently injected with 300 µL of phosphate-buffered saline. To evaluate the separation process, a micropump was used and the flow rate was 
300 µL/min. The collected filtrate volumes were 55 ± 6, 159 ± 10, 197 ± 8, and 220 ± 5 µL for 0.4, 1, 2 and 3 µm pore–sized filters, respectively. (A) The concentration of 
RBCs before and after filtration. (B) The concentration of platelets before and after filtration. (C) The concentration of WBCs before and after filtration. (D) Summary of 
the passage rate of blood components on-chip.
Note: Data are presented as average ± standard error (n = 6).
Abbreviations: WBCs, white blood cells; RBCs, red blood cells.
larger pore sizes allowed more cells and platelets to pass 
through the filter microchip. It should be noted that 0.4 µm 
filters clogged rapidly since the collected volume of filtrate 
was 55 ± 6 µL. The collected filtrate volumes were 159 ± 10, 
197 ± 8, and 220 ± 5 µL for 1, 2 and 3 µm diameter filters, 
respectively. Thus, we selected the 2 µm pore–sized filter 
for further evaluation, as it represented the best balance 
between high selectivity and high filtrate yield.
Secondly, we evaluated the effect of wash volume on 
plasma separation using PBS. For a filter size of 2 µm, the 
collected volumes at the outlet were 103 ± 6, 202 ± 14, 
307 ± 6, and 403 ± 15 µL for wash volumes of 200, 300, 
400, and 500 µL, respectively. The passage rates of WBCs, 
RBCs, and platelets increased as more wash buffer passed 
through a filter (Figure 3). For example, the passage rate 
of platelets increased from 30% to 76% when the wash 
volume increased from 200 to 500 µL. For WBCs, the 
passage rate remained at approximately 10% for the wash 
volumes of 300, 400, and 500 µL. In comparison, the pas-
sage rates of RBCs were 19.1% ± 2.4%, 19.7% ± 2.6%, 
and 29.0% ± 3.1% for the wash volumes of 300, 400, and 
500 µL, respectively. It was observed that the average pas-
sage rate of RBCs (22.6% ± 5.0%) was higher than that of 
WBCs (10.8% ± 2.2%) when the wash volume was larger 
(300–500 µL). These results indicated that larger wash buf-
fer could pass more platelets and RBCs through the filter 
microchip, which may be due to the deformability of RBCs.34 
Thus, we chose a wash volume of 300 µL for the following 
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experiments to maximize the analyte yield and minimize the 
number of blood cells passing through the filter.
Third, we evaluated the effect of flow rate on the pas-
sage rate of blood components, in which a micropump was 
used to set a flow rate ranging from 100 to 500 µL/minute 
(Figure 4). Although the device was designed to be operated 
by manual flow, we evaluated the filtration performance using 
a flow pump to set up flow rates within the range that manual 
pipetting may vary. We observed that the concentrations of 
WBCs in the filtrate remained below 0.2 × 103/µL (Figure 4A). 
In comparison, the concentrations of RBCs increased from 
0.11 × 106 cells/µL to 0.22 × 106 cells/µL, as the flow rate 
increased from 100 to 500 µL/minute (Figure 4B). Under these 
flow rates, the platelet concentration in the filtrate increased 
from 24.3 to 27.7 × 103/µL (Figure 4C). The passage rates 
of blood components at different flow rates are shown in 
Figure 4D. The passage rates of WBCs and platelets were 
not significantly affected by flow rates, with an average pas-
sage rate of 10.8% ± 1.6%, and 65.8% ± 1.9%, respectively. 
There was an increase in the passage rate of RBCs from 
11.5% ± 5.7% to 25.2% ± 5.9%, as the flow rate increased 
from 100 to 500 µL/min. The increase in the passage of RBCs 
could be due to high flow rates that exert more shear stress on 
cells and subsequently force RBCs through the filter pores. 
The passage rates of blood components are summarized in 
Table 1. As shown in Figure 4 and Table 1, the evaluated flow 
rates did not significantly affect the passage rates of blood 
components, which leads to the conclusion that the flow rate 
of manual pipetting (within the evaluated flow-rate range) 
can be used for plasma separation and virus isolation without 
using a micropump.
Lastly, we assessed HIV recovery on-chip by employ-
ing 1 and 2 µm pore–sized filters by manual pipette-based, 
pump-free separation (Figure 5). To prepare HIV samples, 
we spiked three concentrations (103, 104, and 105 RNA 
copies/mL) of HIV into whole blood, because current clini-
cal practice recommends 1000–10,000 RNA copies/mL to 
monitor antiretroviral treatment in resource-constrained 
settings.35–37 The measured HIV concentrations in the 
control (without on-chip filtration) were 624, 12,873, and 
114,390 copies/mL. The measured HIV concentrations 
after filtration using microchips of 1-µm pore size were 
456, 9280, and 85,173 copies/mL, leading to recovery 
rates of 74.5% ± 2.4%, 72.1% ± 2.4%, and 73.1% ± 2.4%, 
respectively (Figure 5A). For the 2 µm pore–size micro-
chip, measured HIV concentrations after filtration were 
488, 10,358, and 102,840 copies/mL, leading to recovery 
rates of 89.9% ± 5.0%, 80.5% ± 4.3%, and 78.2% ± 3.8%, 
respectively (Figure 5A). These data demonstrate that the 
presented device can be potentially used for clinical testing. 
Statistical analysis revealed that 2 µm pore–sized microchips 
had a higher recovery of HIV viruses than 1 µm pore–sized 
microchips only at 1000 copies/mL (P , 0.05). In addi-
tion, we evaluated our devices using anonymous discarded 
HIV-infected patient blood samples (Figure 5B). The results 
showed that 1 µm pore–sized filters had a recovery ranging 
from 74.2% ± 7.3% to 84.6% ± 4.7%, and 2 µm pore–
sized filters had a recovery ranging from 73.1% ± 8.3% to 
82.5% ± 4.1%. One-way analysis of variance showed that 
there was no statistical significance in HIV recovery between 
these two microchips.
The  significant  difference  in  HIV  recovery  at 
1000 copies/mL may be attributed to variations in RT-
PCR at such a low input of HIV RNA in the reaction. At 
1000 copies/mL of HIV spiked in whole blood, loading of 
40 µL blood only led to 40 copies of HIV particles in the 
inlet chamber. Assuming 100% recovery of virus isolation 
and RNA extraction, 7.5 µL of RNA out of 50 µL extract 
in RT resulted in six copies of HIV cDNA (twelve copies 
of LTR DNA), which were further split into two reactions 
of PCR. In this case, only six copies of HIV LTR were 
amplified in PCR, which may have led to the difference in 
HIV recovery at 1000 copies/mL (Figure 5A). By contrast, 
there was no significant difference in HIV recovery at 
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needed in PCR and ELISA for optimal results. As such, 
microfluidic-based isolation of plasma samples would 
facilitate POC testing when integrated with microchip-based 
immunoassay and nucleic acid amplification,5,38–40 as well as 
sensing technologies such as surface plasmon resonance,16 
photonic crystal-based sensors,17 and spectral reflectance 
imaging biosensors.41 The example that we demonstrated 
was virus isolation on-chip, which can facilitate HIV viral 
load testing in resource-constrained settings since the viral 
load is defined as the free circulating viruses in plasma. The 
microchip platform can also be modified to provide sample 
processing for a host of other applications. Since the virus 
size is below 1 µm, the developed filter microchip, in prin-
ciple, can be used as a generic virus–filtration device. Another 
potential application is that the device may be adapted for 
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Figure 4 (A–D) Passage rates of blood components on-chip at different flow rates. 40 µL of blood was injected into the size-based microchips with a pore size of 2 µm at a flow 
rate ranging from 100 to 500 µL/minute. The device was injected with 300 µL of PBS to evaluate the passage rate. The collected filtrate volume was 202 ± 2 µL. Comparisons of 
the concentrations of blood components including RBCs (A), WBCs (B), and platelets (C). The passage rates of RBCs, WBCs and platelets were also compared (D).
Note: Data are presented as average ± standard error (n = 6).
Abbreviations: WBCs, white blood cells; RBCs, red blood cells.
higher concentrations. Nevertheless, we cannot exclude 
the possibility that 2 µm pore–sized microchips may allow 
more free viruses to pass through, since 1 µm pore–sized 
microchips resulted in relatively lower volumes of filtrate. 
The 2 µm pore–sized microchips left 0.13 × 103 cells/µL 
of WBCs (Figure 2) in the filtrate, compared to a standard 
centrifugation protocol (1000 g, twice for 10 minutes), which 
removed nearly 100% of blood cells.
In this study, we demonstrated successful and reli-
able recovery of HIV particles from whole blood using a 
filter-based microchip without requiring a micropump. The 
presented filter microchip can be used to separate plasma 
for POC testing, including initial sample processing in a 
microfluidic-based ELISA or PCR virus-detection system. 
Generally, plasma samples, rather than whole blood, are 
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filtration of mycobacterium TB, which is approximately 
2–4 µm in length and 0.2–0.5 µm in width. This application 
may require pore sizes as large as 4 µm of efficient separa-
tion for mycobacterium TB, since sputum may clog the filter 
easily due to viscosity.
An apparent advantage of the filter microchip is that the 
used materials (10¢ on PMMA, and 67¢ on filter membrane) 
significantly reduce the cost associated with plasma separation 
in a laboratory setting (consumables and a centrifuge). The fil-
ter device was designed to be disposable and inexpensive, thus 
avoiding contamination between samples. In addition, there is 
no involvement of antibodies or nucleic acids in the microchip 
that could degrade with heat or humidity. Thus, the device can 
be robust at various temperature and humidity conditions. 
Although hand-cranked centrifuges can be potentially used to 
provide the required centrifugal forces for plasma separation, 
they require an operator to continuously crank the centrifuge 
over a period of time (eg, 10 minutes), which is tedious and may 
lead to operator-to-operator variations. There have also been 
efforts to use an eggbeater to separate plasma from blood.42 
However, manual centrifugation requires more hands-on time, 
and this process cannot be readily integrated with on-chip 
analytical systems. In comparison, the filter microchip only 
takes a minute to complete the plasma/virus separation, sig-
nificantly decreasing the turnaround time. Another potential 
solution to plasma separation at the POC might be to place a 
filter in a pipette tip. However, the effective filtering area can 
be considerably limited by the size of pipette tips, which may 
result in low yields in plasma separation. In addition, fixing 
the filter in the pipette tips may be technically difficult, and it 
would be difficult to control the flow, thus causing variations 
from operator to operator.
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Figure 5 (A and B) Manual pipette-based, pump-free separation of HIV particles from whole blood using the filter microchip. (A) Whole blood samples spiked with HIV at 
concentrations of 103, 104, and 105 copies/mL, and (B) discarded HIV patient whole blood samples were flowed through filter microchips with membrane pore size of 1 µm 
or 2 µm.
Notes: Subsequently, blood samples containing HIV particles were manually washed with 300 µL of phosphate-buffered saline and all the filtrate (approximately 200 µL) was 
collected. HIV recoveries (%) in both 1 µm and 2 µm filter microchips were then calculated using formula 2. Data are presented as average ± standard error (n = 6). One-way 
analysis of variance was performed. *P , 0.05; in B, x-axis is log-scaled.
Table 1 Effects of device operation parameters on the passage 
rate of blood components
Passage rate (%)
White blood cells Red blood cells Platelets
Pore size (µm)
  0.4   1.4 ± 0.3   0.3 ± 0.1   2.1 ± 0.2
 1   3.1 ± 1.3   1.8 ± 0.2 47.7 ± 3.6
 2 10.5 ± 4.2 18.3 ± 18.3 67.7 ± 5.3
 3 25.1 ± 11.5 49.7 ± 16.0 74.6 ± 9.1
Flow rate (µL/min)
  100   8.6 ± 2.4 11.5 ± 5.7 63.6 ± 6.6
  200 10.2 ± 3.6 15.5 ± 2.9 64.9 ± 4.0
  300 10.5 ± 3.2 19.2 ± 9.9 67.7 ± 9.1
  400 11.8 ± 2.5 21.1 ± 6.6 65.1 ± 7.4
  500 12.9 ± 3.5 25.2 ± 5.9 68.1 ± 5.9
Wash volume (µL)
  200   2.0 ± 1.4   4.6 ± 1.2 30.0 ± 1.0
  300 10.5 ± 4.2 19.2 ± 16.9 67.7 ± 9.1
  400 11.7 ± 3.9 19.7 ± 13.5 72.7 ± 3.3
  500 10.3 ± 3.2 29.0 ± 2.6 76.6 ± 6.6
Notes: For pore-size evaluation, a flow rate of 300 µL/minute and a wash volume 
of 300 µL were used. For flow-rate evaluation, a pore size of 2 µm and a wash 
volume of 300 µL were used. For wash-volume evaluation, a pore size of 2 µm and 
a flow rate of 300 µL/min were used. Data are presented as average ± standard 
error (n = 6).
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Conclusion
In conclusion, we developed a disposable, pump-free, size 
exclusion–based filter microchip that can be used for plasma 
and virus separation from unprocessed whole blood samples 
in resource-constrained settings. Initially, we evaluated the 
microchip at various flow rates and showed that the flow rate 
does not affect the HIV recovery rates from whole blood. 
These evaluated flow rates overlap with range of manual 
pipetting. Then, we demonstrated that the microchip produces 
high yields of separated HIV particles and plasma using 
only manual pipetting, eliminating the complexity of using 
a micropump. Due to its simplicity, this microfluidic device 
can be potentially integrated with HIV microchip diagnostic 
systems, on-chip ELISA and PCR sensing methodologies, 
and optical detection modalities, thus realizing comprehen-
sive sample-to-result testing. This would eliminate the need 
for peripheral instruments for plasma separation. Since the 
pore size of the filter is adjustable, the microchip could be 
broadly adapted for applications targeting other pathogens, 
including viruses such as influenza, allowing rapid sample 
processing and blood screening at the POC.
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